<i>Editorial Commentary:</i>Improving the Treatment of<i>Clostridium difficile</i>–Associated Disease: Where Should We Start?
Bibliographic record
Abstract
There are few common infectious diseases occurring in developed countries for which the treatments used in 2006 are essentially the same as those recommended one-quarter of a century ago. When this happens in resource-poor areas—for example, with leishmaniasis, trypanosomiasis, or leprosy—these infections are labelled “neglected diseases.” The same could be said of Clostridium difficile–associated disease (CDAD). Metronidazole and vancomycin have been used for the treatment of CDAD since the etiological agent was first identified in 1978, although ∼25% of patients treated with these drugs experience at least 1 recurrence of disease [1]. Some of these recurrences are due to reinfections with a new strain (and thus are not due to treatment failure), and others are due to relapses attributable to the original strain [2]. To a large extent, the lack of innovative research into the treatment of CDAD was a consequence of the long-standing perception of C. difficile as a nuisance pathogen (i.e., annoying, but without serious consequences), the management of which could be delegated to the most junior member of the medical staff. In this context, there was little incentive for the pharmaceutical industry to develop novel molecules.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.007 | 0.024 |
| Meta-epidemiology (narrow) | 0.004 | 0.001 |
| Meta-epidemiology (broad) | 0.004 | 0.003 |
| Bibliometrics | 0.002 | 0.002 |
| Science and technology studies | 0.004 | 0.004 |
| Scholarly communication | 0.005 | 0.006 |
| Open science | 0.005 | 0.001 |
| Research integrity | 0.028 | 0.027 |
| Insufficient payload (model declined to judge) | 0.011 | 0.014 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".